Sean MacDonald

Bioneer A/S develops and manufactures drugs. The firm's products and services drug development, molecular histology, dynamic gastric model, biomarkers and drug targets, protein manufacturing, mammalian cell technology, immune targeting, active ingredients and microorganisms. The company was founded in 2003 and is headquartered in Horsholm, Denmark.

Bioneer A/S develops and manufactures drugs. The firm's products and services drug development, molecular histology, dynamic gastric model, biomarkers and drug targets, protein manufacturing, mammalian cell technology, immune targeting, active ingredients and microorganisms. The company was founded in 2003 and is headquartered in Horsholm, Denmark.

Bioneer A/S develops and manufactures drugs. The firm's products and services drug development, molecular histology, dynamic gastric model, biomarkers and drug targets, protein manufacturing, mammalian cell technology, immune targeting, active ingredients and microorganisms. The company was founded in 2003 and is headquartered in Horsholm, Denmark.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Bioneer A/S develops and manufactures drugs. The firm's products and services drug development, molecular histology, dynamic gastric model, biomarkers and drug targets, protein manufacturing, mammalian cell technology, immune targeting, active ingredients and microorganisms. The company was founded in 2003 and is headquartered in Horsholm, Denmark.

Bioneer A/S develops and manufactures drugs. The firm's products and services drug development, molecular histology, dynamic gastric model, biomarkers and drug targets, protein manufacturing, mammalian cell technology, immune targeting, active ingredients and microorganisms. The company was founded in 2003 and is headquartered in Horsholm, Denmark.

Bioneer A/S develops and manufactures drugs. The firm's products and services drug development, molecular histology, dynamic gastric model, biomarkers and drug targets, protein manufacturing, mammalian cell technology, immune targeting, active ingredients and microorganisms. The company was founded in 2003 and is headquartered in Horsholm, Denmark.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Bioneer A/S develops and manufactures drugs. The firm's products and services drug development, molecular histology, dynamic gastric model, biomarkers and drug targets, protein manufacturing, mammalian cell technology, immune targeting, active ingredients and microorganisms. The company was founded in 2003 and is headquartered in Horsholm, Denmark.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Bioneer A/S develops and manufactures drugs. The firm's products and services drug development, molecular histology, dynamic gastric model, biomarkers and drug targets, protein manufacturing, mammalian cell technology, immune targeting, active ingredients and microorganisms. The company was founded in 2003 and is headquartered in Horsholm, Denmark.

Pharmascience, Inc. manufactures and distributes generic and drug products. It offers liquids, tablets, capsules, suppositories, powders, and ophthalmic. The company was founded by Morris Goodman and Ted S. Wise in 1983 and is headquartered in Montr?al, Canada.

Bioneer A/S develops and manufactures drugs. The firm's products and services drug development, molecular histology, dynamic gastric model, biomarkers and drug targets, protein manufacturing, mammalian cell technology, immune targeting, active ingredients and microorganisms. The company was founded in 2003 and is headquartered in Horsholm, Denmark.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Bioneer A/S develops and manufactures drugs. The firm's products and services drug development, molecular histology, dynamic gastric model, biomarkers and drug targets, protein manufacturing, mammalian cell technology, immune targeting, active ingredients and microorganisms. The company was founded in 2003 and is headquartered in Horsholm, Denmark.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.